2024-06-07 05:45:00 ET
Eli Lilly (NYSE: LLY) shares have soared more than 87% over the past year, making this player look more like a growth stock than a slower-paced but steady pharmaceutical stock. Lilly sells a broad range of medicines, but what lately has struck the fancy of investors -- and doctors and patients -- is the company's weight loss portfolio.
Doctors prescribe Lilly's Mounjaro and Zepbound to help patients manage their weight, and the results have been fantastic. This has helped Lilly's revenue soar -- and the share price followed. Though Lilly shares the market with rival big pharma Novo Nordisk , both companies are excelling, with demand for their products outstripping supply.
But could one particular trend represent a threat to Lilly's dominance?
For further details see:
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?